» ACT WONDER2S NEWSLETTER

NEW HIRES

The study team has completed hiring of the core team (excluding 3 CHEs to be hired next year), see details below. We are excited to be fully staffed and making great progress on study goals!



DELILAH PONCE, MHS >>>> Lead Health Educator Delilah has expertise in health education and clinical trials. As Lead Health Educator, she will be focused on health education content development for the ACT WONDER2S study. Melany's expertise involves qualitative research and data analysis. As an Applied Research Scientist for the ACT WONDER2S study, she will be focusing on stakeholder interviews and manuscript writing.

> >>>> Applied Research Scientist I

MELANY GARCIA, PHD





ELLIOTT TAPIA-KWAN, MA >>> Research Coodinator II

Elliott's expertise is centered on qualitative research, writing, and editing. As a Research Coordinator, he will be focused on recruitment, outreach coordination, and data collection for the ACT WONDER2S study.



>>> NCI/CUSP2CT MEETING IN WASHINGTON, DC

Study team members attended the Connecting Underrepresented Populations to Clinical Trials (CUSP2CT) meeting in June. Major points of discussion included: presentations by each U01 site on their proposed interventions and study design, defining and operationalizing "clinical trial referral", and presentations by the working groups including discussions of how each workgroup will operate. The study team members that attended were able to connect with other sites, NCI Program Officers, and Data Evaluation and Coordinating Center (DECC) team members, which fostered collaborative relationships.

ACT WONDER2S Newsletter Summer 2023 Updates



Opinions needed for study on experiences with clinical trials

would like to learn more about your experiences with clinical trials and what mation you would like to receive about clinicals trials as part of your health care.

Are 18 years or older Identify as Black, African American Hispanic, or Latino -dispanic, or Latino Are an English or Spanish speaker Reside in the Tampa Bay area or

ig counties er been a Moffitt patien b-based interview

mpensated \$50 for you

act the ACT WONDERS





QUALITATIVE INTERVIEW RECRUITMENT

Aim 1 Phase 1 qualitative interviews to refine intervention content are well under way!

Completed Interviews as of September 1st, 2023

- Moffitt physicians 5 out of 5
- Moffitt clinical research coordinators 9 out of 10
- Moffitt patients 2 out of 10
- Community physicians 3 out of 10
- Community residents 5 out of 10

Rapid analysis focusing on the functionality of the digital tools of Moffitt physician interviews are complete and will also be conducted for other stakeholder groups. Formal thematic content analysis will follow. Aim 1 Phase 2 interviews and User Centered Design processes will begin later this Fall/Winter. Thank you to all co-investigators who have helped facilitate gualitative interviews by assisting with the development of the interview guides and recommending physician colleagues, patients, or community groups as potential avenues for recruitment!

DIGITAL TOOL DEVELOPMENT



PRECISION ENGAGEMENT TOOL (PET)

We have made significant progress on designing the high-level architecture for various digital tools that will be developed for ACT WONDERS including the Precision Engagement Tool (PET), Trial Connect Portal (TCP), and the Recruitment Dashboard. Specifically, our study bioinformatician (co-I Eschrich) has taken the lead in conceptualizing a framework for the application development. While the specific functionality of these digital tools will be based on stakeholder feedback, our team is currently developing prototypes that can be customized to include specific functionality stakeholder once the feedback is finalized.

ACT WONDER2S Newsletter Summer 2023 Updates

DIGITAL TOOL DEVELOPMENT (CONT'D.)

Example CTML document



Welcome to the CHOICES Decision Aid website! In this website, we provide information and tools to help cancer patients and their families learn more about cancer clinical trials, and make decisions about joining a clinical trial.



CHOICES DA HOME PAGE

The Biostatistics and Bioinformatics Shared Resource (BBSR) staff working on this team, led by Dr. Eschrich, has begun to test the MatchMiner tool for use in the TCP. This tool incorporates clinical trial markup language (CTML) which can be used to match a patient to a specific trial. Work is also underway to use the existing Cancer InFocus Tool developed by the University of Kentucky as the Core application for the PET tool. In terms of the Recruitment Dashboard, study team members have had meetings with Moffitt's Business Intelligence Department to discuss refinement and revisions to existing clinical trial recruitment dashboards. The study team is also in the process of assessing updates needed to the CHOICES DA patient decision aid and educational tool, with revisions planned to begin this Fall as a part of the UCD/LV process.

EDUCATION & CHE-LED INTERVENTION COMPONENTS

II. Intervention Demo: CHE-led component examples 🛛 🖗



The study team has begun content development for all CHE-led education components, particularly the training of future study CHEs to be hired early next year. In addition to developing content and modules for the 2-day CHE training, the team is developing a training manual with pre- and post-2 day training focused on clinical trials, diversity, and working with community members and community physicians, along with practical work incorporates mock presentations that and shadowing community, Moffitt, and outreach workers. Development of content for community physician CME events and Moffitt physician implicit bias training will begin this fall.

hank you

WE HAVE COME SO FAR, AND STILL HAVE MORE TO GO!

BE SURE TO LOOK OUT FOR ADDITIONAL UPDATES!